Bao_et_al_2021_Exploring the antibiotics innovation system.pdf (795 kB)
Exploring the antibiotics innovation system and R&D policies in China: mission oriented innovation?
report
posted on 2023-06-10, 00:57 authored by Yuhan Bao, Adrian ElyAdrian Ely, Michael HopkinsMichael Hopkins, Xianzhe Li, Yangmu HuangOne possible response to the growing problem of Antimicrobial Resistance (AMR) in pathogenic infections is the development of new types of antibiotics. However, the pharmaceutical companies that have traditionally led such innovation face a lack of incentives at the present time due to high levels of market uncertainty and low expected returns. Mission oriented innovation with coordinated investment and market-shaping policies may offer an approach to accelerating antibiotic innovation. This paper aims to evaluate whether preCovid-19 Chinese policies concerning AMR can be seen as constituting a mission-oriented approach and whether these policies have influenced antibiotics innovation in China. It adopts a mixed method approach to deliver several insights. By using historical event analysis based on data collected from interviews, public and commercial databases as well as policy documents, the paper finds that China’s recent actions concerning AMR since 2008 comprise many elements of mission-oriented innovation policy. The National Action Plan to Contain AMR has provided a clear mission since 2016 to tackle the problem of AMR and provides the opportunity to coordinate and integrate these policies into a more coherent and evolving mission-oriented innovation approach. Analysis of relevant research grants and publications suggest that these policies (including the 2016 National Action Plan) have drawn the scientific community towards antibiotics research and provided more support to this area. Case studies following the development of new antibiotics are used to illustrate how the established elements of mission oriented innovation policy have or have not contributed to antibiotics innovation in China. Further research is required to more comprehensively analyse R&D investments, and to understand the effects of recent policies, especially after 2016.
Funding
CHNUK: Integrated platforms from science to policy in response to antibacterial resistance; G3055; MRC-MEDICAL RESEARCH COUNCIL
History
Publication status
- Published
File Version
- Published version
ISSN
2057-6668Publisher
Science Policy Research Unit, University of SussexPages
33.0Place of publication
UKDepartment affiliated with
- SPRU - Science Policy Research Unit Publications
Notes
https://www.sussex.ac.uk/business-school/people-and-departments/spru/research/working-papersInstitution
University of SussexFull text available
- Yes
Legacy Posted Date
2021-09-14First Open Access (FOA) Date
2021-09-14First Compliant Deposit (FCD) Date
2021-09-14Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC